Zambon in the USA
Zambon USA Team
Together with their European colleagues, the American team has been laying the groundwork in preparation for two commercial launches, pending positive data and receiving the necessary regulatory approvals.
Peter has more than 20 years of global commercial expertise in strategic and operational marketing and sales functions with leadership roles in the U.S., Europe, Latin America and Asia Pacific.
Peter is responsible for the development of Zambon USA and is leading the U.S. commercial organization for Zambon’s CNS, anti-infective and severe respiratory disease portfolios. In his role as Head of Global Marketing Specialty Care, he is responsible for Zambon’s global CNS and severe respiratory drug portfolios. Prior, he served as Chief Commercial Officer at Breath Therapeutics, until the company’s acquisition by Zambon SpA in 2019.
Prior to joining Breath Therapeutics, Peter was the Global Marketing Lead at Vertex for its next-generation corrector programs for the treatment of cystic fibrosis. Previously, he served as Vice President and Global Business Leader at Lundbeck and led the global product launch of BRINTELLIX® (renamed TRINTELLIX®), a novel antidepressant. Earlier in his career, Peter served as Director of International and Global Commercial Strategy at Gilead Sciences and was responsible for the hepatitis, anti-fungal and respiratory therapeutic franchises. At Gilead, he also oversaw the U.S. and international commercial teams for the global commercial launch of VIREAD® for hepatitis B. Peter has also held several commercial positions with Novartis in Europe, the U.S. and South America.
Peter earned a bachelor’s degree in economics from Yale University and is a graduate of the Ecole Supérieure de Commerce de Paris. He holds a dual U.S. and French citizenship and is fluent in French, German, English and Spanish.
Shahid is a dynamic and results-oriented global leader with over 25 years of experience managing clinical development and medical affairs programs at large, mid-size and small biopharmaceutical companies. Over the course of his career, he has held roles of increasing responsibility at AstraZeneca, Eli Lilly, Novartis, CHIRON, and most recently at Regeneron.
At Zambon USA, he currently oversees all strategic medical, clinical and related (e.g., regulatory, pharmacovigilance) activities related to the NCFB and BOS development programs. In due course, Shahid will be responsible for building the medical/clinical team in the U.S., which will be integral to Zambon SpA’s presence in the U.S.
Prior to joining Zambon USA in May of 2022, Shahid served as Executive Director of Medical Affairs, Immunology at Regeneron, where he was responsible for leading a team of MDs and MSLs focused on the upper and lower airways in multiple respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and chronic rhinosinusitis with nasal polyps (CRSwNP). Here, he also led global registries in asthma and CRSwNP and published many post-hoc analyses from the company's pivotal studies.
During his tenure as a clinical lead at AstraZeneca for BEVESPI AEROSPHERE® in COPD, Shahid played a critical role in the successful development and submission of regulatory drug applications to global health authorities, pivotal trial recruitment and execution, and product launches in the U.S. and global markets. In addition, he had the opportunity to work on first-in-class biologic products, such as FASRENA® and DUPIXENT® in multiple therapeutic indications.
Shahid has co-authored more than 34 manuscripts, published in top-tier journals, and has presented numerous study findings at key international medical congresses. Prior to taking on industry roles, Shahid worked as a clinical practitioner, having completed his residency in medicine at Jinnah Post Graduate Medical Center in Karachi, Pakistan. He also earned his master’s degree in Health Management at Ohio University.